Revolutionizing animal care

This audio recording was enabled by AI

'I got my dog back'

A dog with itch due to skin allergies is serious business. If you are a pet parent, you may watch helplessly as your dog scratches its ears, chews and bites its paws and skin—all day and night. With every scratch, the dog’s tag jingles, the bed shakes, the animal’s skin gets redder and rawer, and you suffer because you don’t know how to bring relief to your furry friend.

Dermatological problems for dogs are not new, but in recent years, innovative treatments have brought relief to millions of dogs¹ with allergic itch around the world. “The first thing our scientists do is to dig deep into what triggers the allergic skin disease. Then, we get to work and figure out how to stop or prevent it,” said Andrea Gonzales, who led dermatology research and development at Zoetis before she retired in 2025.

The resulting treatments can be life-changing for dogs and their families. Just ask veterinarian Jayne Clark, National Veterinary Manager in the U.K. for Zoetis’ pain portfolio. Her energetic and “full of character” Wire Hair Fox Terrier named Leffe began itching her feet, flanks, belly and ears when she was a year old. “Especially in the evening, she spent most of her time licking and scratching herself. Leffe’s fur and paws were discolored, and her coat was smelly and greasy—I referred to her as a little yeasty biscuit.”

Having a dog with allergic skin disease is difficult for the pet, the pet’s owner and the family’s veterinarian. “There is a phenomenon called ‘caregiver burden,’ and it refers to the emotional, physical, social and other pressures of managing pets with chronic conditions like allergic skin disease,” said veterinarian Michelle Greaves, Zoetis’ National Veterinary Manager for dermatology and anti-infectives in the U.K. “Coping with allergic skin disease leads to a strain on the pet owner and pressure on the veterinarian to provide a solution for a complex disease.”

Game-changing treatments to help ditch the itch

More than 15 million² dogs in the U.S.—and countless others in more than 90 countries—have found relief from allergic itch with Apoquel^® (oclacitinib tablet) from Zoetis. Apoquel* works by blocking Janus kinases enzymes, which send troublesome signals that our scientists know cause itch and inflammation in dogs with allergic skin disease.

Over 9 million³ U.S. dogs, along with others in more than 40 countries have also benefitted from another breakthrough in Zoetis' dermatology portfolio—Zoetis’ injectable treatment, Cytopoint^©, the first monoclonal antibody therapy used to provide long-lasting relief for dogs with allergic skin disease. Cytopoint is a biological medication (a protein, not a chemical) that works like the dog’s immune system to target and neutralize proteins that send signals of allergic itch to the dog’s brain, triggering itching, licking and chewing.

“I started Leffe with Apoquel daily—the chewable was great because she thought it was a treat. Later, I switched her to a once-a-month Cytopoint injection, which gave me one less thing to think about on daily basis,” said Jayne. “Now, Leffe’s doing very well and is back to being a real character, walking her own path and doing whatever suits her. Her skin is now a normal color, and she’s not itching all the time. I feel far more relaxed, because I’m not worrying about her being uncomfortable.”

The availability of Apoquel and Cytopoint “has changed the course of veterinary dermatology in a way I never thought possible,” said Michelle. “I worked in a veterinarian practice before our dermatology products were developed. Consultations with pet owners were difficult because treatment options were very limited. Today, the most satisfying part of my job at Zoetis is seeing the way our products have changed the lives of pets and their owners.”

How serious is all that itching?

Dogs itch for a variety of reasons. There’s normal itching—an occasional tickle behind the ear or nibble to dislodge the debris clinging to the leg. “But when scratching becomes more frequent and uncomfortable for your pet (and you), it’s important to find out why,” said Olivier Martinon, who’s spent the past 15 years leading Zoetis scientists in the development of Cytopoint. “Persistent scratching could be a warning there’s a parasitic infestation or a chronic or seasonal skin allergy.”

Research shows a common reason people take their dogs to the veterinarian is because of skin allergies.⁴ Consider pets in the U.S.: Veterinarians diagnose 15% of the dogs they see with itch due to skin allergies.⁵

“If untreated, skin allergies can get worse and cause even more problems, like fur loss, paw lesions and bacterial and fungal infections, making life even more miserable for the dog and the entire family,” said Olivier.

‘Her quality of life was decreasing. It was very stressful on our family

Andrea experienced the suffering firsthand. Her family lives on a lake and enjoys hiking and swimming with their Labrador retrievers. “All of our dogs have been diagnosed with skin allergies, but Piper suffered the worst. She would itch like crazy. You could see she was struggling, and her quality of life was decreasing. It was very stressful on our family.”

Piper’s struggles with allergic skin disease made Andrea’s work at Zoetis especially fulfilling. She joined the company in 2007 to work in early research for Apoquel. “At the time, there was very little work that had been done in the scientific community to understand what made dogs itch,” said Andrea. “My first job with the company was to understand the role of cytokines, the small proteins that ‘talk’ to the immune system so it will kick into action, and how Apoquel could block those cytokines from communicating in dogs with allergic skin disease.”

Ultimately, Apoquel was approved in the U.S. in 2013. “Once Piper was on Apoquel, within an hour, she started to calm down. She was comfortable and not itchy for the first time since her diagnosis,” said Andrea. “At that moment, it hit me: We are a part of something very special. We were so excited when we saw the study results and the data Apoquel generated, but when that innovation directly impacts your pet? That’s the most rewarding of all.”

What life-altering innovations are on the horizon in pet dermatology?

Zoetis has a strong track record of life-altering treatments in canine dermatology, but Olivier says, “There’s much more we can do. A significant unmet need exists for new dermatological treatments to help other companion animals. And where there’s a need, we aim to find a solution.”

That’s where ZINC comes in. The Zoetis Incubator of Northern Colorado launched in January 2020 to use the most advanced science to focus on immune-related diseases and find potential new solutions.

“At the incubator, we have some of the finest immunologists and data scientists working together with the university ecosystem to push the boundaries of research to gain a deeper understanding of disease biology,” said Chad Ray, who leads the incubator. “We aim to find the next innovative therapy—something that’s even better than what we have—and something that will lead to faster resolution of disease for companion animals.”

When ZINC opened in January 2020, Zoetis scientists were focused on building our understanding of the livestock immune system to pave the way for new alternatives to antibiotics in food-producing animals. The team has identified several substrates in vivo and in vitro and is now looking to scale them in the target species. Given the successful partnership model with Colorado State University, and the opportunity for growth in the allergy and dermatology space for companion animals, Zoetis recently expanded ZINC to include additional lab space dedicated to companion animal projects.

Pets can rest a bit easier nowadays knowing the Zoetis scientists are on the case.

Updated on October 22, 2025

Related Content

Zoetis Announces FDA Approval of Apoquel^® Chewable

Zoetis continues to lead in dermatology innovation with a new formulation, which is expected to demonstrate comparable efficacy to that of Apoquel (oclacitinib tablet) after the first dose.

Learn more

CYTOPOINT INDICATIONS: Cytopoint has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

APOQUEL AND APOQUEL CHEWABLE INDICATIONS: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL AND APOQUEL CHEWABLE IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines. See full Prescribing Information at apoqueltabletandchewablepi.com.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2013-2025 Zoetis Services LLC. All rights reserved.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. APQ-01407R1

References:

*Apoquel tablet launched Jan 2014, Apoquel Chewable launched October 2023.
¹ Kynetec PetTrak – GAH-284: Unique Patient Count Since Launch Custom Report: Apoquel-Cytopoint January 2014 – March 2025.
² Kynetec PetTrak – GAH-284: Unique Patient Count Since Launch Custom Report: Apoquel: December 2024 to March 2025.
³ Kynetec PetTrak – GAH-284: Unique Patient Count Since Launch Custom Report: Cytopoint: December 2024 to March 2025.
⁴ Nationwide. Most Common Medical Conditions that Prompt Veterinary Visits- 2024. Mar 19 2025. Retrieved April 7 2025 from https://news.nationwide.com/chronic-vs-acute-the-most-frequent-diagnoses-and-their-costs. 
⁵ Data on file. Zoetis, Inc. 2021.